Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000950103-18-003689
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-23 15:03:18
Reporting Period:
2018-03-21
Accepted Time:
2018-03-23 15:03:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
895051 Casi Pharmaceuticals Inc. CASI Biological Products, (No Disgnostic Substances) (2836) 581959440
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1491503 Quan Zhou Unit 5505, The Centre
99 Queen's Road Central
K3
Yes No Yes No
1508829 L.p. Iii Fund Growth China Idg-Accel Unit 5505, The Centre
99 Queen's Road Central
K3
No No Yes No
1545806 Sing Chi Ho Unit 5505, The Centre
99 Queen's Road Central
K3
No No Yes No
1550192 L.p. Associates Iii Fund Growth China Idg-Accel Unit 5505, The Centre
99 Queen's Road Central
K3
No No Yes No
1550193 L.p. Investors Iii China Idg-Accel Unit 5505, The Centre
99 Queen's Road Central
K3
No No Yes No
1564281 Ltd. Associates Iii Gp Fund Growth China Idg-Accel Unit 5505, The Centre
99 Queen's Road Central
K3
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-03-21 2,882,098 $3.19 9,126,375 No 4 P Direct
Common Stock Acquisiton 2018-03-21 204,320 $3.19 646,995 No 4 P Indirect See Explanation of Responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Indirect See Explanation of Responses
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant Acquisiton 2018-03-21 1,152,839 $0.13 1,152,839 $3.69
Common Stock Warrant Acquisiton 2018-03-21 1,152,839 $0.13 81,728 $3.69
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,152,839 2018-09-17 2023-03-21 No 4 P Direct
81,728 2018-09-17 2023-03-21 No 4 P Indirect
Footnotes
  1. These securities are directly owned by IDG-Accel China Growth Fund III L.P. ("IDG-Accel Growth") and may be deemed to be indirectly beneficially owned by the other reporting persons. IDG-Accel China Growth Fund III Associates L.P. ("IDG-Accel Associates") is the general partner of IDG-Accel Growth. IDG-Accel China Growth Fund GP III Associates Ltd. ("IDG-Accel GP") is the general partner of both IDG-Accel Associates and IDG-Accel China III Investors L.P. ("IDG-Accel Investors"). Chi Sing Ho and Quan Zhou are shareholders and directors of IDG-Accel GP. Pursuant to a securities purchase agreement dated as of March 19, 2018 by and among the Issuer and certain investors (the "Purchase Agreement"), IDG-Accel Growth purchased 2,882,098 shares of common stock and warrants to purchase 1,152,839 shares of common stock of the Issuer.
  2. These securities are directly owned by IDG-Accel Investors and may be deemed to be indirectly beneficially owned by the other reporting persons. Pursuant to the Purchase Agreement, IDG-Accel Investors purchased 204,320 shares of common stock and warrants to purchase 81,728 shares of common stock of the Issuer.
  3. The shares of common stock and the warrants were issued in units consisting of one share of common stock and a right to purchase 0.4 shares of common stock. The purchase price was $3.24 per unit. The filing of this statement by the reporting persons shall not be deemed an admission that such persons are, for purposes of Section 16 of the Securities and Exchange Act of 1934 or otherwise, the beneficial owner of any equity securities covered by this statement.